- Home
- / Celgene
Celgene
Revenue
$15.3 B
FY, 2018
Celgene Summary
Company summary
- Overview
- Celgene is an integrated global biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology, and neuroinflammation.
- Type
- Subsidiary
- Founded
- 1986
- HQ
- Summit, NJ, US | view all locations
- Website
- http://www.celgene.com/
- Cybersecurity rating
Key people
Zeba M. Khan, Vice President Corporate Responsibility
John Vogler, Director Environment, Health & Safety
Reimund Tauer, Director, CAR T Commercial Operations
Operating MetricsView all
Phase III Trials Products (Inflammation and Immunology)
4
100.0%
FY, 2018
Filed Trials Products (Solid Tumors)
4
FY, 2018
Phase I Trials Products (Cellular Therapies)
2
FY, 2016
LocationsView all
3 locations detected
Summit, NJ HQ
United States
86 Morris Ave
Singapore
Singapore
200 Newton Road #04-01, Newton 200
Boudry, Neuchâtel
Switzerland
Route de Perreux 1
Celgene Financials
Summary financials
- Revenue (Q3, 2019)
- $4.5B
- Gross profit (Q3, 2019)
- $4.4B
- Net income (Q3, 2019)
- $1.7B
- Cash (Q3, 2019)
- $9.6B
- EBIT (Q3, 2019)
- $2.3B
